TABLE 2.
Comparison of SUVmax on 68Ga-FAP-2286 and 18F-FDG PET/CT Images in Primary and Metastatic Tumors
| Tumor type | n | 68Ga-FAP-2286 | 18F-FDG PET/CT | P | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Size (cm) | Positive tumors | SUVmax | TBR | Positive tumors | SUVmax | TBR | Median SUVmax (FAP-2286 vs. 18F-FDG) | TBR (FAP-2286 vs. 18F-FDG) | ||
| Primary | ||||||||||
| Total§ | 46 | 3.2 (0.9–11.3) | 46 | 11.1 (2.5–28.9) | 9.2 (1.1–31.5) | 37 | 6.9 (1.5–19.1) | 3.0 (0.9–13.2) | <0.001 | <0.001 |
| HNC | 7 | 1.7 (1.5–3.4) | 7 | 16.8 (11.0–20.2) | 13.7 (8.1–15.3) | 7 | 11.0 (4.0–15.6) | 7.0 (2.9–13.1) | 0.043 | 0.043 |
| Breast cancer* | 6 | 1.5 (0.9–7.0) | 6 | 9.9 (6.0–18.3) | 10.1 (3.9–22.3) | 4 | 6.4 (1.5–17.3) | 5.0 (1.1–13.2) | 0.249 | 0.075 |
| Esophageal cancer | 4 | 4.1 (2.1–9.0) | 4 | 22.9 (10.0–26.4) | 13.6 (6.3–19.4) | 4 | 11.6 (7.9–18.4) | 5.8 (4.7–8.6) | 0.068 | 0.068 |
| Lung adenocarcinoma | 2 | 2.9 (1.1–4.7) | 2 | 7.5 (5.7–9.3) | 10.0 (9.2–10.9) | 2 | 6.1 (3.3–8.9) | 7.1 (4.2–10.0) | NA | NA |
| Gastric cancer | 6 | 2.0 (1.2–4.5) | 6 | 9.1 (4.1–13.0) | 9.2 (4.9–12.7) | 3 | 3.4 (1.7–7.9) | 2.0 (0.9–4.1) | 0.028 | 0.028 |
| Hepatic cancer | 8 | 5.2 (0.9–11.3) | 8 | 11.3 (2.5–28.9) | 5.2 (1.5–9.4) | 5 | 4.8 (3.1–9.7) | 1.5 (1.0–3.5) | 0.917 | 0.028 |
| Pancreatic cancer | 7 | 3.4 (2.4–5.7) | 7 | 13.0 (10.7–22.7) | 12.2 (5.7–23.3) | 6 | 6.5 (3.0–8.1) | 2.9 (1.1–4.4) | 0.018 | 0.018 |
| Renal cancer | 1 | 4.5 (NA) | 1 | 6.1 (NA) | 1.5 (NA) | 1 | 4.1 (NA) | 2.0 (NA) | NA | NA |
| Ovarian cancer | 5 | 4.8 (1.7–6.2) | 5 | 10.8 (6.0–25.6) | 11.0 (5.0–31.5) | 5 | 9.6 (5.3–12.2) | 6.9 (2.8–9.3) | 0.345 | 0.138 |
| Recurrence/mets | ||||||||||
| Recurrent tumor (total†) | 9 | 2.9 (0.7–5.1) | 9 | 5.8 (2.9–16.5) | 4.7 (2.2–15.7) | 3 | 3.8 (2.2–7.6) | 1.1 (0.8–5.4) | 0.015 | 0.008 |
| LN mets (total) | 107 | 1.2 (0.5–6.6) | 105 | 10.6 (3.0–20.1) | 9.0 (2.2–30.0) | 91 | 6.2 (1.3–21.2) | 3.7 (1.0–13.0) | <0.001 | <0.001 |
| Lung mets | 21 | 0.9 (0.4–1.3) | 16 | 3.4 (0.6–10.2) | 4.9 (0.9–14.5) | 19 | 3.5 (0.7–7.1) | 5.0 (1.0–10.2) | 0.876 | 0.931 |
| Hepatic mets | 30 | 2.6 (0.9–10.7) | 27 | 6.9 (2.4–12.2) | 4.1 (0.9–8.4) | 22 | 6.8 (2.1–10.8) | 2.2 (0.9–3.9) | 0.484 | <0.001 |
| Peritoneal mets | 70 | NA‡ | 69 | 8.6 (2.4–15.4) | 6.7 (1.8–27.0) | 46 | 4.6 (1.5–11.4) | 2.4 (0.8–8.1) | <0.001 | <0.001 |
| Subcutaneous mets | 12 | 0.9 (0.6–2.0) | 12 | 8.1 (5.2–12.4) | 9.3 (6.3–20.4) | 5 | 1.4 (0.7–7.4) | 1.3 (1.0–11.6) | 0.002 | 0.002 |
| Bone mets | 38 | 1.0 (0.4–3.1) | 38 | 6.6 (3.8–13.3) | 10.1 (2.9–26.7) | 22 | 2.7 (0.9–11.4) | 2.4 (0.9–19.3) | <0.001 | <0.001 |
One patient was diagnosed with multifocal breast cancer (4 primary tumors).
Local recurrent tumors included glioblastoma (n = 1), HNC (n = 4), hepatic cancer (n = 3), and gastric cancer (n = 1).
Lesion size cannot be calculated because of diffuse type of peritoneal metastases (irregular shape).
Primary tumors were not located in 2 patients with head and neck cancer of unknown primary etiology; 2 patients were therefore excluded from analysis. Two patients were diagnosed with synchronous double cancer (one with esophageal and lung adenocarcinoma, the other with HNC and renal cancer).
HNC = head and neck cancer; NA = not applicable; mets = metastases; LN = lymph node.
Qualitative data are number; continuous data are median and range.